{
    "clinical_study": {
        "@rank": "6573", 
        "arm_group": [
            {
                "arm_group_label": "standard group", 
                "arm_group_type": "Active Comparator", 
                "description": "patients in this group received standard statin treatment\uff1a Atorvastatin statins 20mg / night ."
            }, 
            {
                "arm_group_label": "intensive group", 
                "arm_group_type": "Experimental", 
                "description": "patients in this group received intensive statin treatment\uff1a Admission atorvastatin statins the 80mg, after surgery\uff0catorvastatin 40mg / night\uff0cand until 30 days after the operation , and thereafter 20mg / night ."
            }
        ], 
        "brief_summary": {
            "textblock": "First acute anterior myocardial infarction in patients with primary PCI preoperative and\n      postoperative 30 days intensive dose atorvastatin statin therapy compared with conventional\n      -dose therapy , patients can improve left ventricular function , reduce major adverse\n      cardiovascular events ."
        }, 
        "brief_title": "Effects of Intensive Statin Treatment on Left Ventricular Function", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Anterior Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction", 
                "Anterior Wall Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. \u2265 18 years of age\n\n          2. the first time clinical diagnosis of acute anterior myocardial infarction , the time\n             of onset \u2264 12 hours ,intends underwent emergency PCI\n\n          3. informed consent\n\n        Exclusion Criteria:\n\n          1. Taking , or the need for long-term use of statins is greater than the initial dose\n\n          2. treated with PCI again within a mouth\n\n          3. active liver disease or liver dysfunction\n\n          4. the diagnosis of myopathy\n\n          5. severe renal insufficiency ( serum creatinine > 178umol / L )\n\n          6. Statin drug allergy or had a serious adverse reaction\n\n          7. severe aortic stenosis or mitral stenosis , hypertrophic obstructive cardiomyopathy ,\n             pericardial disease\n\n          8. pregnancy\n\n          9. malignancy or any other end-stage diseases result in a life expectancy of < 6 months\n\n         10. be participating in other clinical studies\n\n         11. not suitable for inclusion of the other cases\n\n         12. not treated with PCI"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936103", 
            "org_study_id": "NH-20120404"
        }, 
        "intervention": [
            {
                "arm_group_label": "standard group", 
                "description": "standard statin treatment:Atorvastatin statins 20mg / night .", 
                "intervention_name": "standard group", 
                "intervention_type": "Drug", 
                "other_name": "Lipitor"
            }, 
            {
                "arm_group_label": "intensive group", 
                "description": "intensive statin treatment\uff1a Admission atorvastatin statins the 80mg, after surgery\uff0catorvastatin 40mg / night\uff0cand until 30 days after the operation", 
                "intervention_name": "intensive group", 
                "intervention_type": "Drug", 
                "other_name": "intensive Lipitor"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atorvastatin", 
                "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute anterior myocardial infarction", 
            "Percutaneous coronary stent implantation", 
            "Intensive statin therapy", 
            "Left ventricular function"
        ], 
        "lastchanged_date": "September 2, 2013", 
        "location": {
            "contact": {
                "last_name": "Wang Geng, Dr", 
                "phone": "13309886393"
            }, 
            "facility": {
                "address": {
                    "city": "Shenyang", 
                    "country": "China", 
                    "state": "Liaoning", 
                    "zip": "110016"
                }, 
                "name": "Shenyang Northen Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Intensive Statin Therapy on Left Ventricular Function for Patients With the First Acute Anterior Myocardial Infarction After Directly to Percutaneous Coronary Intervention.", 
        "other_outcome": [
            {
                "description": "the level of CK peak", 
                "measure": "enzymes", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "1 year after death, cardiac death , myocardial infarction , heart failure , cardiac causes hospitalization , revascularization combined endpoint of cerebrovascular events .", 
                "measure": "Major adverse cardiac and cerebral events at 1 year", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Aspartate aminotransferase (AST) returned to normal in the perioperative period", 
                "measure": "Aspartate aminotransferase (AST)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "CK-MB peak", 
                "measure": "enzymes", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "troponin (TnT)", 
                "measure": "enzymes", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "CK-MB peak time", 
                "measure": "enzymes", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "any elevation> 3 times the proportion", 
                "measure": "Aspartate aminotransferase (AST)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "alanine aminotransferase (ALT)returned to normal in the perioperative period", 
                "measure": "alanine aminotransferase (ALT)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "any elevation> 3 times the proportion", 
                "measure": "alanine aminotransferase (ALT)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "overall_contact": {
            "email": "Wanggeng69@hotmail.com", 
            "last_name": "Geng Wang, Dr", 
            "phone": "+86-24-28897280"
        }, 
        "overall_official": {
            "affiliation": "Shenyang Northern Hospital", 
            "last_name": "Geng Wang, Dr", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "ultrasonic observation of left ventricular end-diastolic diameter", 
                "measure": "left ventricular function", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "ultrasonic observation of left ventricular end-systolic volume", 
                "measure": "left ventricular function", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "ultrasonic observation of left ventricular fractional shortening RWSI", 
                "measure": "left ventricular function", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "ultrasonic observation of the left ventricular ejection fraction", 
                "measure": "left ventricular function", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "ultrasonic observation of E/A", 
                "measure": "left ventricular function", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936103"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shenyang Northern Hospital", 
            "investigator_full_name": "Han Yaling, MD", 
            "investigator_title": "vice president", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "the left ventricular function", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "the left ventricular function", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "plasma brain natriuretic peptide", 
                "safety_issue": "No", 
                "time_frame": "30days"
            }, 
            {
                "measure": "plasma brain natriuretic peptide", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "plasma brain natriuretic peptide", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Shenyang Northern Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shenyang Northern Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}